For the second generation CAR design, 4-1BB-incorporated CAR-T cells show milder activation and longer persistence than CD28-incorporated CAR-T cells, which leads to enhanced in vivo efficacy in preclinical tumor models (37–39). Here, CD28 is linked to neoplasm.